MedTech sales organizations are using artificial intelligence — just not in the parts of the sales process that carry the most deal value, according to an analysis published by MedTech Intelligence.

The finding matters because medical technology selling is a long-cycle, high-compliance trade. If AI tools sit only at the margins — drafting emails, summarizing calls — the measurable impact on win rates and cycle times stays small, whatever vendors claim.

What did the analysis actually find?

The report's core observation is a gap between where AI is deployed and where it would do the most work. Teams have picked up the easy, low-risk applications. The harder, higher-value uses — those touching deal strategy, territory decisions, and customer-facing judgment — remain largely manual.

The source does not publish adoption percentages, sample sizes, or methodology details in the material available. That absence is itself worth flagging: readers should treat the conclusion as a directional industry observation, not a measured benchmark.

Why does medtech lag other verticals?

Regulated selling environments move slowly by design. In medtech:

• Claims to clinicians and hospitals must survive compliance review, which makes teams cautious about AI-generated content.
• Long sales cycles involving multiple stakeholders resist the quick-win automation that AI vendors demo best.
• Procurement and evidentiary requirements mean a wrong AI-assisted claim carries real cost, not just embarrassment.

These constraints do not prevent AI use. They channel it toward safe tasks.

What is measured versus asserted?

What the analysis documents is a pattern of deployment — where tools are and are not in use. What it asserts, without published figures, is that the current placement is the wrong one. Both parts can be true; only the first carries data weight in the available text.

Sales leaders reading vendor pitches in this space should ask the same questions of any tool claim: What share of the team actually uses it weekly? Where in the pipeline — prospecting, qualification, negotiation, renewal — does it intervene? What outcome moved, and against what baseline?

What should teams watch next?

The gap the report identifies is an opportunity as much as a critique. If competitors figure out compliant ways to apply AI to core selling work first, the advantage compounds across every cycle that follows.